GEAP202416532A - Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof - Google Patents

Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof

Info

Publication number
GEAP202416532A
GEAP202416532A GEAP202416532A GEAP2024016532A GEAP202416532A GE AP202416532 A GEAP202416532 A GE AP202416532A GE AP202416532 A GEAP202416532 A GE AP202416532A GE AP2024016532 A GEAP2024016532 A GE AP2024016532A GE AP202416532 A GEAP202416532 A GE AP202416532A
Authority
GE
Georgia
Prior art keywords
usp1
specific protease
small molecule
molecule inhibitors
ubiquitin specific
Prior art date
Application number
GEAP202416532A
Other languages
English (en)
Georgian (ka)
Inventor
Jianping Wu
Jinxin Liu
Luoheng Qin
Original Assignee
Insilico Medicine Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insilico Medicine Ip Ltd filed Critical Insilico Medicine Ip Ltd
Publication of GEAP202416532A publication Critical patent/GEAP202416532A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GEAP202416532A 2021-11-12 2022-11-11 Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof GEAP202416532A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021130290 2021-11-12
CN2022123827 2022-10-08

Publications (1)

Publication Number Publication Date
GEAP202416532A true GEAP202416532A (en) 2024-08-12

Family

ID=86335131

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP202416532A GEAP202416532A (en) 2021-11-12 2022-11-11 Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof

Country Status (19)

Country Link
US (3) US20250026754A1 (https=)
EP (1) EP4430050A4 (https=)
JP (1) JP2024543477A (https=)
KR (1) KR20240117556A (https=)
CN (1) CN119053601A (https=)
AR (1) AR127646A1 (https=)
AU (1) AU2022386486A1 (https=)
CA (1) CA3235765A1 (https=)
CL (2) CL2024001397A1 (https=)
CO (1) CO2024006269A2 (https=)
CR (1) CR20240191A (https=)
DO (1) DOP2024000080A (https=)
GE (1) GEAP202416532A (https=)
IL (1) IL312642A (https=)
JO (1) JOP20240096A1 (https=)
MX (1) MX2024005755A (https=)
PE (1) PE20241307A1 (https=)
TW (1) TW202334142A (https=)
WO (1) WO2023083286A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20240191A (es) 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
WO2024086790A1 (en) * 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制pkmyt1之化合物治療癌症之方法
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
WO2025227060A1 (en) 2024-04-26 2025-10-30 Insilico Medicine Ip Limited Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337611A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE69921358T2 (de) * 1998-12-23 2006-03-09 Bristol-Myers Squibb Pharma Co. Stickstoffhaltige heterobicyclen als faktor-xa-hemmer
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
ITFR20030005U1 (it) 2003-03-17 2003-06-16 C D R Sistema di protezione solare (frangisole f1)
JP2010208945A (ja) 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
EP2370437B1 (en) 2008-11-25 2013-09-04 Nerviano Medical Sciences S.r.l. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
SG10201407012XA (en) 2009-10-29 2014-11-27 Genosco Kinase inhibitors
US8541418B2 (en) 2009-12-23 2013-09-24 Elan Pharmaceutical, Inc. Inhibitors of polo-like kinase
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US9242981B2 (en) * 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
AU2011376721B2 (en) 2011-09-16 2017-06-08 Sanofi Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
CA2896731A1 (en) 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CN104311555B (zh) 2014-09-19 2016-04-20 广东东阳光药业有限公司 吡唑并哌啶酮类化合物及其组合物及用途
US9763922B2 (en) 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
US10189841B2 (en) * 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
EP3464286B1 (en) 2016-05-24 2021-08-18 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのrasスーパーファミリーと相互作用する化合物
WO2019089216A1 (en) 2017-11-01 2019-05-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancers
BR112021010715A2 (pt) * 2018-12-20 2021-11-16 Ksq Therapeutics Inc Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)
JP7553450B2 (ja) * 2018-12-28 2024-09-18 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ1を阻害するための組成物
CA3168009A1 (en) * 2020-02-14 2021-08-19 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
EP4161494A4 (en) 2020-06-02 2024-07-17 KSQ Therapeutics, Inc. NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS
KR20230098186A (ko) 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
TW202246255A (zh) 2021-02-12 2022-12-01 美商傳達治療有限公司 Cdk抑制劑及其使用方法
US20240182481A1 (en) 2021-02-15 2024-06-06 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
AU2022238886A1 (en) 2021-03-17 2023-09-14 Medivir Ab Purine derivatives as anticancer agents
WO2022199652A1 (en) 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
MX2023011709A (es) 2021-04-07 2023-10-12 Forma Therapeutics Inc Inhibidor de la proteasa 1 especifica de ubiquitina (usp1).
EP4321515A4 (en) 2021-04-09 2025-06-25 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. UBIQUITIN-SPECIFIC PROTEASE-1 INHIBITOR
EP4430041A4 (en) 2021-11-12 2025-09-24 Insilico Medicine Ip Ltd SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES
CR20240191A (es) 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
GEAP202416531A (en) 2021-11-12 2024-10-28 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2024086790A1 (en) 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS

Also Published As

Publication number Publication date
CL2025001068A1 (es) 2025-07-11
US20250026754A1 (en) 2025-01-23
US20240190839A1 (en) 2024-06-13
PE20241307A1 (es) 2024-06-24
MX2024005755A (es) 2024-09-06
CR20240191A (es) 2024-09-13
CL2024001397A1 (es) 2024-10-25
JOP20240096A1 (ar) 2024-04-24
AU2022386486A1 (en) 2024-05-09
EP4430050A4 (en) 2025-09-24
WO2023083286A1 (en) 2023-05-19
US11739077B2 (en) 2023-08-29
US12570634B2 (en) 2026-03-10
CN119053601A (zh) 2024-11-29
EP4430050A1 (en) 2024-09-18
TW202334142A (zh) 2023-09-01
CA3235765A1 (en) 2023-05-19
AR127646A1 (es) 2024-02-14
IL312642A (en) 2024-07-01
US20230183210A1 (en) 2023-06-15
KR20240117556A (ko) 2024-08-01
JP2024543477A (ja) 2024-11-21
DOP2024000080A (es) 2024-11-29
CO2024006269A2 (es) 2024-05-30

Similar Documents

Publication Publication Date Title
GEAP202416531A (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
GEAP202416532A (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
CR20240189A (es) Inhibidores de molécula pequeña de proteasa específica de ubiquitina 1 (usp1) y usos de los mismos
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
MY209609A (en) Immunomodulators, compositions and methods thereof
MXJL05000010A (es) Compuestos de fenil-aza-benzimidazol para modular la ige e inhibir la proliferacion celular.
ZA202304734B (en) Alpha protein kinase 1 inhibitors and methods of use
MXJL05000009A (es) Compuestos de fenilindon para modular la ige e inhibir la proliferacion celular.
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
JOP20250215A1 (ar) ثيازولو[4،5-d]-بيريميدين-7-ونات كمثبطات NOX4
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
MX2021013602A (es) Inhibidores de jak.
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
ATE501128T1 (de) 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion
SA521422728B1 (ar) مثبطات فوسفوينوسيتيد 3- كيناز الموضعية
SA523440367B1 (ar) مشتقات تترازول كمثبطات لمستقبل عابر أنكيرين قوي 1
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
ATE329909T1 (de) 1,2,3-triazolamid-derivate als cytokininhibitoren
MX2025014163A (es) Azinas condensadas como inhibidores de tyk2 y usos de las mismas
ATE443044T1 (de) Tace inhibitoren
WO2024137700A3 (en) Polynucleic acid molecules targeting agt and uses thereof
MX2023011012A (es) Compuestos farmaceuticos como inhibidores de proteasa 19 especifica de ubiquitina (usp19).
BR112022005608A2 (pt) Inibidores de jak
BR112022002390A2 (pt) Inibidores de jak